Heidelberg Pharma 
Welcome,         Profile    Billing    Logout  
 6 Products   31 Diseases  6 Products   4 Trials   343 News 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed
3
300
Europe, Canada, US, RoW
89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)
Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd
Clear Cell Renal Cell Carcinoma
10/22
11/22
2008-004548-35: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER

Ongoing
2
9
Europe
cG250, cG250,
Radboud university nijmegen medical centre
Patients with metastatic clear cell renal cell carcinoma
 
 
OPALESCENCE, NCT04758780: Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients

Recruiting
2
12
Europe
89Zr-TLX250 PET/CT
Institut Cancerologie de l'Ouest, Telix Pharmaceutical, SIRIC ILIAD
Triple Negative Breast Cancer
03/24
06/24
STARLITE 2, NCT05239533: Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

Recruiting
2
41
US
177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT, 177Lu whole body (WB) planar and SPECT/CT scans
Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
03/26
03/26
NCT05563272: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Recruiting
2
100
US
89Zr-DFO-girentuximab
Telix International Pty Ltd
Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
12/25
12/25
Zip Up, NCT05018442: 89Zr-girentuximab PET in Urothelial Cancer Patients

Recruiting
1/2
12
RoW
89Zr-Girentuximab
Telix International Pty Ltd
Urothelial Carcinoma, Bladder Cancer
02/22
05/22
STARLITE-1, NCT05663710: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Recruiting
1/2
100
US
177Lu girentuximab, Nivolumab, BMS-936558, Opdivo, Cabozantinib, XL-184, XL184, ArabinoFuranosylGuanine [18F]F-AraG
M.D. Anderson Cancer Center, Telix Pharmaceuticals Limited, United States Department of Defense
Advanced Cancer, Clear Cell Renal Cell Carcinoma
10/25
10/27
ACTRN12621000411842: A single-centre, open-label, phase I study to evaluate the diagnostic performance of 89Zirconium-labelled girentuximab (89Zr-TLX250) Position Emission Tomography (PET) in Urothelial Cancer Patients

Not yet recruiting
1
20
 
South Metropolitan Health Services, Telix International Pty Ltd
Metastatic urothelial carcinoma, Bladder cancer
 
 
NCT02497599: Intraoperative Dual-modality Imaging in Renal Cell Carcinoma

Recruiting
1
30
Europe
Indium-111-DOTA-Girentuximab-IRDye800CW, Dual-labeled girentuximab, SPECT/CT, Intraoperative dual-modality imaging, Fluorescence and radioguided surgery
Radboud University Medical Center
Carcinoma, Renal Cell
12/21
04/22
ZiPUP, NCT05046665: Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

Completed
1
11
RoW
89Zr-Girentuximab
South Metropolitan Health Service, Telix Pharmaceuticals (Innovations) Pty Limited
Urothelial Carcinoma
08/22
08/22
PERTINENCE, NCT04897763: Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)

Completed
1
6
Europe
89Zr-TLX250 PET/CT
Institut Cancerologie de l'Ouest, ATONCO
Bladder Cancer
08/22
09/22
ZIRDOSE-CP, NCT05861778: Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

Completed
1
10
RoW
89Zr-Girentuximab, 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx
Telix International Pty Ltd, Grand Pharmaceutical (China) Co., Ltd.
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
11/23
11/23
NCT05868174: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Recruiting
1
36
RoW
89Zr-TLX250, 89Zr-DFO-girentuximab, 177Lu-TLX250 and Peposertib, 177Lu-DOTA-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited, Merck KGaA, Darmstadt, Germany
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma
12/24
12/26
NCT01582204: Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Active, not recruiting
N/A
17
US
124IcG250
Memorial Sloan Kettering Cancer Center, Telix Pharmaceutical
Renal Cancer
04/26
04/26
Mesupron (upamostat) / RedHill
PROTECT-APT 1, NCT05954286: Early Treatment and Post-Exposure Prophylaxis of COVID-19

Active, not recruiting
2
300
US, RoW
Upamostat, WX-671, RHB-107, Placebo (PO)
Henry M. Jackson Foundation for the Advancement of Military Medicine, Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies, RedHill Biopharma Limited, FHI Clinical, Inc.
SARS-CoV-2
05/25
10/25
pamlectabart tismanitin (HDP-101) / Heidelberg Pharma
2020-003414-12: A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma

Not yet recruiting
1/2
78
Europe
HDP-101, Powder for concentrate for solution for infusion
Heidelberg Pharma AG, Heidelberg Pharma AG
Relapsed or refractory Multiple Myeloma (r/r MM), Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
HDP-101-01, NCT04879043 / 2020-003414-12: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Recruiting
1/2
78
Europe, US
HDP-101
Heidelberg Pharma AG, Heidelberg Pharma AG
Multiple Myeloma, Plasma Cell Disorder
08/25
05/26
WX-UK1 / RedHill
No trials found
MGTA-XX-ATACs / Magenta Therap, Heidelberg Pharma
No trials found
HDP-103 / Heidelberg Pharma
No trials found
CD19-ATAC / Heidelberg Pharma
No trials found
HDP-102 / Heidelberg Pharma
No trials found
HDP-104 / Heidelberg Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed
3
300
Europe, Canada, US, RoW
89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)
Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd
Clear Cell Renal Cell Carcinoma
10/22
11/22
2008-004548-35: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER

Ongoing
2
9
Europe
cG250, cG250,
Radboud university nijmegen medical centre
Patients with metastatic clear cell renal cell carcinoma
 
 
OPALESCENCE, NCT04758780: Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients

Recruiting
2
12
Europe
89Zr-TLX250 PET/CT
Institut Cancerologie de l'Ouest, Telix Pharmaceutical, SIRIC ILIAD
Triple Negative Breast Cancer
03/24
06/24
STARLITE 2, NCT05239533: Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

Recruiting
2
41
US
177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT, 177Lu whole body (WB) planar and SPECT/CT scans
Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
03/26
03/26
NCT05563272: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Recruiting
2
100
US
89Zr-DFO-girentuximab
Telix International Pty Ltd
Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
12/25
12/25
Zip Up, NCT05018442: 89Zr-girentuximab PET in Urothelial Cancer Patients

Recruiting
1/2
12
RoW
89Zr-Girentuximab
Telix International Pty Ltd
Urothelial Carcinoma, Bladder Cancer
02/22
05/22
STARLITE-1, NCT05663710: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Recruiting
1/2
100
US
177Lu girentuximab, Nivolumab, BMS-936558, Opdivo, Cabozantinib, XL-184, XL184, ArabinoFuranosylGuanine [18F]F-AraG
M.D. Anderson Cancer Center, Telix Pharmaceuticals Limited, United States Department of Defense
Advanced Cancer, Clear Cell Renal Cell Carcinoma
10/25
10/27
ACTRN12621000411842: A single-centre, open-label, phase I study to evaluate the diagnostic performance of 89Zirconium-labelled girentuximab (89Zr-TLX250) Position Emission Tomography (PET) in Urothelial Cancer Patients

Not yet recruiting
1
20
 
South Metropolitan Health Services, Telix International Pty Ltd
Metastatic urothelial carcinoma, Bladder cancer
 
 
NCT02497599: Intraoperative Dual-modality Imaging in Renal Cell Carcinoma

Recruiting
1
30
Europe
Indium-111-DOTA-Girentuximab-IRDye800CW, Dual-labeled girentuximab, SPECT/CT, Intraoperative dual-modality imaging, Fluorescence and radioguided surgery
Radboud University Medical Center
Carcinoma, Renal Cell
12/21
04/22
ZiPUP, NCT05046665: Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

Completed
1
11
RoW
89Zr-Girentuximab
South Metropolitan Health Service, Telix Pharmaceuticals (Innovations) Pty Limited
Urothelial Carcinoma
08/22
08/22
PERTINENCE, NCT04897763: Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)

Completed
1
6
Europe
89Zr-TLX250 PET/CT
Institut Cancerologie de l'Ouest, ATONCO
Bladder Cancer
08/22
09/22
ZIRDOSE-CP, NCT05861778: Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

Completed
1
10
RoW
89Zr-Girentuximab, 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx
Telix International Pty Ltd, Grand Pharmaceutical (China) Co., Ltd.
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
11/23
11/23
NCT05868174: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Recruiting
1
36
RoW
89Zr-TLX250, 89Zr-DFO-girentuximab, 177Lu-TLX250 and Peposertib, 177Lu-DOTA-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited, Merck KGaA, Darmstadt, Germany
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma
12/24
12/26
NCT01582204: Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Active, not recruiting
N/A
17
US
124IcG250
Memorial Sloan Kettering Cancer Center, Telix Pharmaceutical
Renal Cancer
04/26
04/26
Mesupron (upamostat) / RedHill
PROTECT-APT 1, NCT05954286: Early Treatment and Post-Exposure Prophylaxis of COVID-19

Active, not recruiting
2
300
US, RoW
Upamostat, WX-671, RHB-107, Placebo (PO)
Henry M. Jackson Foundation for the Advancement of Military Medicine, Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies, RedHill Biopharma Limited, FHI Clinical, Inc.
SARS-CoV-2
05/25
10/25
pamlectabart tismanitin (HDP-101) / Heidelberg Pharma
2020-003414-12: A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma

Not yet recruiting
1/2
78
Europe
HDP-101, Powder for concentrate for solution for infusion
Heidelberg Pharma AG, Heidelberg Pharma AG
Relapsed or refractory Multiple Myeloma (r/r MM), Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
HDP-101-01, NCT04879043 / 2020-003414-12: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Recruiting
1/2
78
Europe, US
HDP-101
Heidelberg Pharma AG, Heidelberg Pharma AG
Multiple Myeloma, Plasma Cell Disorder
08/25
05/26
WX-UK1 / RedHill
No trials found
MGTA-XX-ATACs / Magenta Therap, Heidelberg Pharma
No trials found
HDP-103 / Heidelberg Pharma
No trials found
CD19-ATAC / Heidelberg Pharma
No trials found
HDP-102 / Heidelberg Pharma
No trials found
HDP-104 / Heidelberg Pharma
No trials found

Download Options